02552 HUA MEDICINE-B
- 1.730
- 0.0000.00%
HUA MEDICINE-B News
HUA MEDICINE-B: INTERIM REPORT 2024
A visual guide to understanding the 2024 interim report of Hualing Pharmaceuticals-B (02552.HK)
On August 29, Hualing Pharmaceuticals-B(02552.HK) released its 2024 interim report. The following infographic will help you understand it.
Express News | Hua Medicine H1 Pretax Profit RMB -142.2 Million
Express News | Hua Medicine H1 Revenue RMB 102.7 Million
HUA MEDICINE-B: INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2024
Hualing Pharmaceuticals-B (02552.HK) held a board of directors meeting on August 29 to consider and approve the mid-term performance.
China State-Owned Enterprise Hualing Pharmaceutical (02552.HK) announced that the board of directors meeting will be held on Thursday, August 29, 2024 to consider and approve the interim performance of the group ending on June 30, 2024, and related announcements, as well as to deal with other matters.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Hualing Pharmaceuticals announced at the 2024 ADA Scientific Conference the potential of using Dapagliflozin in combination with SGLT-2 inhibitors.
Shanghai, June 24, 2024 / PRNewswire / - Hualei Medicine ("the Company", Stock Code: 2552.HK) announced today that it demonstrated multiple basic research results at the 84th American Diabetes Association (ADA) Scientific Sessions, including pioneering innovative drugs GKA Duvoglitazone which reduces blood glucose levels by promoting the secretion of insulin and GLP-1 through dual activation of glucose kinase. Duvoglitazone and SGLT-2 inhibitor Caglitinib are used in combination. This research was conducted by the Company and its wholly-owned subsidiary, Nanjing Shengderui'er Pharmaceutical Technology Co., Ltd. (Shengderui'er).
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) CEO Compensation Is Looking A Bit Stretched At The Moment
HKEX Buzz: Hualei Pharmaceutical-B (02552) rose more than 4% and will exhibit multiple research achievements at the American Diabetes Association conference in 2024.
Hua Ling Pharmaceutical - B (02552) rose more than 4%, as of the time of publication, up 4.43% to HKD 1.65, with a turnover of HKD 1.684 million.
HUA MEDICINE-B: Annual Report 2023
Hualing Pharmaceutical (02552) announces 2023 results: R&D expenses of about 172 million yuan to actively promote the overseas market layout of second-generation GKA
On March 28, Hualing Pharmaceutical (02552) announced its 2023 results
HUA MEDICINE-B: ANNUAL RESULTS ANNOUNCEMENT FORTHE YEAR ENDED DECEMBER 31, 2023
Hualing Pharmaceutical-B (02552.HK) held a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 18 | Hualing Pharmaceutical-B (02552.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve, including the Group's annual results for the year ended December 31, 2023, and the proposed final dividend (if any), and other matters.
HUA MEDICINE-B: Date of Board Meeting
Changes in Hong Kong stocks | Hualing Pharmaceutical-B (02552) rose more than 6%. Second-generation GKA submitted an IND application to the US FDA, Huatangning's sales volume can be expected
Hualing Pharmaceutical-B (02552) rose more than 6%. As of press release, it rose 6.19% to HK$2.4, with a turnover of HK$6.734,900.
Home Linjiang: Hong Kong stocks in 2024, or the continuation of the structured market...
The Hang Seng Healthcare Index has generally produced good companies over the past few years, and they deserve a lot of attention from investors in 2024.
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US
Hualing Pharmaceutical-B (02552) submitted a new drug clinical trial application for a second-generation glucokinase ectopic activator to the FDA and was accepted
Jinwu Financial News | Hualing Pharmaceutical-B (02552) announced that the company has submitted a new drug clinical trial (IND) application to the US Food and Drug Administration for a second-generation glucokinase ectopic activator (second-generation GKA) to initiate a phase I randomized, double-blind, placebo-controlled, single-dose, safety, tolerability, pharmacokinetics and pharmacodynamics study for type 2 diabetes (T2D) subjects in the US. This IND application is the first step in the company's strategy to expand its innovative approach to “repair sensors, restore homeostasis, and treat diabetes at source” to regions outside of mainland China, and its first generation
Dogliatetin was successfully selected into the medical insurance catalogue, and commercialization of Hualing Pharmaceutical-B (2552.HK) accelerated
The annual health insurance negotiations came to an end, and a new list was finally released at the end of the year. Judging from the results, in addition to the regular customers that appear every year, fresh blood has also joined this time, including the world's first innovative drug, Huatangning (doglietine tablets) independently developed by Hualing Pharmaceutical. It is worth noting that behind this new FIC drug, which has brought breakthrough treatment plans to many diabetics, Hualing Pharmaceutical's stock price has also shown a recovery trend recently, driven by favorable news such as Bayer's 800 million milestone payment and expected inclusion in health insurance. So, what are the signals behind this new health insurance adjustment worth paying attention to? Hualing Pharmaceutical Enters
Analysis
Price Target
No Data
No Data